| CPC A61K 36/53 (2013.01) [A61K 9/0053 (2013.01); A61K 9/16 (2013.01); A61K 31/164 (2013.01); A61K 31/355 (2013.01); A61K 36/23 (2013.01)] | 11 Claims |
|
1. A method for reducing the main modifiable risk factors of vascular cognitive impairment (VCI) comprising orally administering an oral formulation comprising an association consisting of Bacopa monnieri, astaxanthin, vitamin E, L-theanine and Centella asiatica as the active ingredient and optionally at least one of the following active ingredients selected from the group consisting of palmitoylethalonamide (PEA), eleutherococcus and Theobroma cacao wherein
i) said association is in the form of an oral formulation, said oral formulation containing said association as the only active ingredient in combination with suitable excipients and/or diluents, and in said oral formulation:
Bacopa monnieri is contained in an amount between 70 to 200 mg with a minimum titre in bacosides of 10%;
astaxanthin is contained in said association in a minimum content of 1 mg;
vitamin E is contained in said association in a maximum amount of 60 mg;
L-theanine is contained in the said association in amounts ranging from 150 to 300 mg;
Centella asiatica is present in amounts of 75 to 250 mg with a minimum titre in tot terpen (as asiaticoside) of 10%,
ii) said main risk factor are neuro-inflammation due to oxidative stress, alteration of oxygen supply and neuronal trophic alteration or alteration of neurotransmission mediated by acetylcholine.
|